<DOC>
	<DOC>NCT02081001</DOC>
	<brief_summary>The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.</brief_summary>
	<brief_title>PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Males or females diagnosed with type 1 diabetes mellitus for at least 24 months Current usage of subcutaneous insulin pump treatment Age 1865 years Cpeptide level &lt; 0.5 ng/ml Willingness to follow all study procedures, including attending all clinic visits Subject has provided informed consent and has signed and dated an informed consent form before any trialrelated activities Pregnant and/ or Lactating: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. HbA1c &gt;10.0% Renal insufficiency (serum creatinine of 1.2 mg/dL or greater) Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum bilirubin of over 2.0. Hematocrit of less than or equal to 34% Congestive heart failure, NYHA class II, III or IV History of coronary artery disease Active foot ulceration History of a cerebrovascular accident Active alcohol abuse or substance abuse Active malignancy, except basal cell or squamous cell skin cancers Major surgical operation within 30 days prior to screening Seizure disorder Current administration of oral or parenteral corticosteroids Use of an investigational drug within 30 days prior to screening Bleeding disorder, treatment with warfarin, or platelet count below 50,000 Proliferative or severe nonproliferative retinopathy Gastroparesis Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von HippelLindau disease) Insulinoma Allergies to glucagon or glucagonlike products, or any history of significant hypersensitivity to glucagon or any related products. Glycogen storage disease Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Any reason the principal investigator deems exclusionary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypoglycemia</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Artificial Pancreas</keyword>
</DOC>